Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Rhea-AI Summary
Penumbra (NYSE: PEN) will host an investor event at the 2025 TCT Conference on October 26, 2025 from 4:00–5:00 PM PT / 7:00–8:00 PM ET to discuss the STORM-PE clinical trial with management and the STORM-PE steering committee. A live webcast will be available on the company's Investors > Events and Presentations page and remain on the site for at least two weeks after the event.
The company also scheduled its Q3 2025 earnings release and conference call for after market close on November 5, 2025, with the call at 4:30 PM ET. The press release with third-quarter financial results will be issued after market close the same day. The conference call dial-in is (888) 596-4144 (conference id: 6572573) and a webcast will be available on the same investor events page for at least two weeks.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PEN gained 0.94%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The Company also announced that it will host a conference call to discuss financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025 at 4:30 PM Eastern Time. A press release with third quarter 2025 financial results will be issued after market close that day. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-schedules-investor-event-at-tct-conference-on-october-26-2025-earnings-release-and-conference-call-for-third-quarter-2025-scheduled-for-november-5-2025-302578797.html
SOURCE Penumbra, Inc.